Kadmon Holdings, Inc.
- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy -
NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that data from the pivotal ROCKstar clinical trial of REZUROCK™ (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD) were published in the journal Blood. The ROCKstar data served as the basis for the Company's New Drug Application (NDA) for REZUROCK for the treatment of cGVHD, which was granted full approval by the U.S. Food and Drug Administration (FDA) on July 16, 2021 for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy.
"Belumosudil is very effective in inducing responses across all organs affected by cGVHD and is safe and well tolerated. It is exciting to see the development of new interventions that can help patients," said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School; Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute and ROCKstar study investigator.
"Leveraging ROCK inhibition to address both the immune and fibrotic components of cGVHD is a welcome step forward in the treatment of this debilitating disease."
"The results from ROCKstar showcase the benefit that belumosudil can provide to cGVHD patients, including reducing and eliminating corticosteroid and calcineurin inhibitor doses and achieving improvements in quality of life," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We are pleased by the recent FDA approval of REZUROCK and look forward to making the drug available to patients in the near term."
As previously reported, data from ROCKstar, the randomized, Phase 2 clinical trial of belumosudil, which enrolled 132 cGVHD patients who had received two to five prior lines of therapy, demonstrated an Overall Response Rates (ORR) of 74% (95% Confidence Interval (CI): 62, 84; p<0.0001) with 200 mg once daily (QD) and 77% (95% CI: 65, 87; p<0.0001) with 200 mg twice daily (BID). Responses were achieved across patient subgroups and complete responses were observed in all organ systems, including in lung. Responses were durable, with a median duration of 54 weeks, which represents the total combined response periods for each patient. Forty-four percent (44%) of responders maintained their response for ≥1 year. In addition, clinically meaningful improvement from baseline in the Lee Symptom Scale (LSS) score, a chronic GVHD symptom measurement, with belumosudil was observed in 61% of patients. During treatment, 65% of patients were able to reduce their corticosteroid dose, with 21% of patients completely discontinuing corticosteroid therapy. In addition, 22% of patients completely discontinued calcineurin inhibitor therapy. Belumosudil was well tolerated and adverse events have been consistent with those expected in patients with advanced cGVHD receiving corticosteroids and/or other immunosuppressants.
The Blood publication of the ROCKstar data is available online here.
About cGVHD
cGVHD is a complication that can occur following allogeneic stem cell transplantation, resulting in significant morbidity and mortality. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are living with cGVHD.
About REZUROCK™ (belumosudil)
REZUROCK™ (belumosudil) is the first and only approved therapy targeting Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and fibrotic processes. REZUROCK is approved in the United States for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. For more information, visit www.REZUROCK.com.
Kadmon is also developing belumosudil for the treatment of systemic sclerosis. The FDA has granted Orphan Drug Designation to belumosudil for the treatment of systemic sclerosis.
INDICATIONS AND USAGE
REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, REZUROCK can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use effective contraception.
Adverse Reactions
The most common (≥20%) adverse reactions, including laboratory abnormalities, in patients receiving REZUROCK were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.
To report suspected adverse reactions, contact Kadmon at 1-877-377-7862 or the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
Use in Specific Populations
Lactation: Advise not to breastfeed.
Please visit www.REZUROCK.com to see the full Prescribing Information for REZUROCK.
About Kadmon
Kadmon is a biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. REZUROCK™ (belumosudil), an oral, once-daily, tablet, is approved in the United States for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Kadmon's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. For more information, please visit www.kadmon.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations regarding REZUROCK™ (belumosudil) as a new available therapy, the timing of commercial availability of REZUROCK in the U.S., the commercial launch of REZUROCK in the U. S. and the potential benefit of our clinical and preclinical development programs for immune and fibrotic diseases as well as immuno-oncology therapies. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," "contemplate" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statement contained in this press release, including, without limitation, (i) our ability to commercialize REZUROCK and execute on our marketing plans for any other drugs or indications that may be approved in the future, (ii) risks that REZUROCK revenue, expenses and costs may not be as expected, (iii) risks relating to REZUROCK's market acceptance, competition, reimbursement and regulatory actions, (iv) risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, including, without limitation, commercial and clinical drug supply chain continuity and the commercial launch of REZUROCK, (v) our ability to obtain and maintain reimbursement for REZUROCK and any approved product and the extent to which patient assistance programs and copay programs are utilized, (vi) our ability to successfully demonstrate the efficacy and safety of our product candidates including in later-stage studies, (vii) availability and timing of data from our preclinical and clinical trials, which may not support further development of our product candidates, (viii) our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers, (ix) actions of regulatory agencies, (x) the inherent uncertainty in estimates of patient populations and incidence and prevalence estimates, (xi) competition from other products, (xii) our ability to comply with healthcare regulations and laws, (xiii) our ability to obtain, maintain and enforce our intellectual property rights, (xiv) our ability to maintain and establish strategic agreements and collaborations and the potential benefits of those arrangements and (xv) other risks, including active or potential litigation risks, any or all of which of the foregoing may affect the initiation, timing and progress of clinical studies and the timing of and our ability to obtain additional regulatory approvals, and make our investigational drugs and REZUROCK available to patients, and to derive revenue from product sales. More detailed information about us and the risk factors that may affect the realization of our forward-looking statements are set forth in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, except as may be required by law. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Contact Information
Ellen Cavaleri, Investor Relations
646.490.2989
ellen.cavaleri@kadmon.com
SOURCE: Kadmon Holdings, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655991/Kadmon-Announces-Pivotal-Trial-Data-Published-in-the-Journal-Bloodfor-REZUROCKTM-Belumosudil-in-Chronic-Graft-Versus-Host-Disease-cGVHD
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202530.6.2025 23:40:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2025 of $37,507,184 Total cash as at April 30, 2025 of $2,475,945 Working capital deficiency as at April 30, 2025 of $527,130 Shareholder's equity as at April 30, 2025 of $33,668,042 During the quarter, the Company incurred $584,284 in cost for exploration activities at the Thunder Bay North project. The team performed drilling and follow-up geophysics activities at the Current Deposit, that were focused on expanding the high-grade ballrooms in the Lower Current and Bridge zones. The results of this program were critical in aiding the Company towards developing a revised high-grade
Karbon-X Acquires ALLCOT, Expanding Global Climate Solutions Platform30.6.2025 15:00:00 CEST | Press release
The acquisition unites climate policy expertise and emissions strategy with digital infrastructure and delivery at scale - accelerating trusted, measurable climate action worldwide. CALGARY, AB / ACCESS Newswire / June 30, 2025 / Karbon-X (OTCQX:KARX), an end-to-end climate solutions company, today announced the acquisition of ALLCOT, a global advisory firm with a legacy of supporting climate policy, carbon markets, and high-integrity project development. This acquisition brings together two complementary forces under one shared mission: to scale science-backed, verifiable climate solutions across industries and regions. Karbon-X's leadership in emissions tracking, verified portfolios, and climate strategy combined with Allcot's legacy of policy guidance, project credibility, and regional expertise form a unified climate solutions provider with end-to-end capabilities across both voluntary and compliance markets. "This is about unlocking scale with integrity," said Chad Clovis, CEO of
Eagle Football Holdings supports Leadership Changes at Olympique Lyonnais30.6.2025 09:30:00 CEST | Press release
PALM BEACH GARDENS, FL / ACCESS Newswire / June 30, 2025 / Eagle Football Holdings Limited today confirmed its support of leadership changes which shall occur at its subsidiary Eagle Football Group (France) and Olympique Lyonnais. John Textor, Chairman and majority owner of Eagle Football Holdings, acting in his capacity as the sole director, and on behalf of the sole shareholder, of Olympique Lyonnais, today appointed Michael Gerlinger to the position of Director General (CEO), and Michele Kang to the position of Chair and President. Mr. Textor has resigned from his leadership positions at Olympique Lyonnais, in favor of the appointment of Ms. Kang and Mr. Gerlinger. Michele Kang, who is also a leading shareholder of Eagle Football Holdings, has served on the OL board since 2023, has been appointed Chair and President. She will take an active role in supporting OL's executive management, including spearheading the club's appeal process with the DNCG. Michael Gerlinger, currently Chief
CEVA Joins Windrose To Test Long-Haul EV Trucking in China27.6.2025 19:00:00 CEST | Press release
ANTWERP, BELGIUM / ACCESS Newswire / June 27, 2025 / CEVA Logistics in Greater China is coming together with Windrose, leading heavy-duty electric truck provider, to conduct a feasibility study for the deployment of long-haul electric vehicle (EV) trucking in China. This collaboration marks a significant step forward in CEVA's commitment to sustainability and its pioneering efforts to lead the sustainable development of the logistics industry. Under this partnership, CEVA and Windrose have successfully conducted trials of long-haul electric trucking, including a round-trip journey from Greater Bay Area in Guangdong to Pingxiang, Guangxi, at the China-Vietnam border, and a 5,000-kilometer journey from Shenzhen to Alashankou, at the China-Kazakhstan border. These pilot runs resulted in a remarkable carbon emissions reduction of approximately 55% on average (WTW) per GLEC framework. Based on these successes, CEVA and Windrose will continue to conduct trial runs within China to further exp
GA-ASI Announces Investment in Dutch Technology Innovator Arceon26.6.2025 19:00:00 CEST | Press release
Selection Follows Successful Pitch During Blue Magic Netherlands Event SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 26, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) announces an investment in another Dutch business, Arceon, following the inaugural Blue Magic Netherlands (BMN) event held in November 2024. GA-ASI is a global leader in unmanned aircraft systems and related mission systems. GA-ASI selected Arceon following a compelling pitch they made during the BMN event and after detailed business and technology discussions with GA-ASI and GA's affiliates, General Atomics Energy and General Atomics Electromagnetic Systems. Arceon joins Emergent Swarm Solutions and Saluqi Motors as companies receiving investment from GA-ASI following the BMN event. Arceon is revolutionizing high-performance ceramic composites through their innovative, fast, scalable, and cost-effective melt infiltration process. Their cutting-edge Carbeon carbon-ceramic components - engineered for applicat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom